Dt120

Phase 3

DDefinium Therapeutics US, Inc.

Dt120 is one of 77 therapeutic programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Major Depressive DisorderRecruiting

Generalized Anxiety DisorderActive, not recruiting

Major Depressive DisorderPhase 3

Recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

2 2

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 3

Bupropion XL

GSK

Phase 3

1 4

SPD489

Takeda

Phase 3

3 5

Venlafaxine ER

Pfizer

Phase 3

2 6

MK0869, Aprepitant

Merck & Co.

Phase 3

4 7

Antidepressant Therapy

AbbVie

Phase 3

4 8

Saredutant

Sanofi

Phase 3

3 9

Vraylar

AbbVie

Phase 3

—10

NMRA-335140

NNeumora Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06741228

Q1 2027

Phase 3Active, not recruiting

Major Depressive Disorder

NCT06941844

Q2 2027

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06809595

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT07592689

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend

Recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT07592689·165 enrolled

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06941844·149 enrolled

Generalized Anxiety Disorder2 trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06741228·214 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06809595·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Dt120. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dt120. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Definium Therapeutics US, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDefinium Therapeutics US, Inc.

Dt120

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q2 2028

Trials by Indication[1]

Major Depressive Disorder2 trials

Generalized Anxiety Disorder2 trials

References

Drug Info

Quick Facts

Related News